Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 54       

   Table of Contents      
Year : 2016  |  Volume : 144  |  Issue : 4  |  Page : 587-591

Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination

Department of Bioinformatics, Science Campus, Alagappa University, Karaikudi, India

Date of Submission02-Mar-2014
Date of Web Publication24-Feb-2017

Correspondence Address:
Karthikeyan Muthusamy
Department of Bioinformatics, Science Campus, Alagappa University, Karaikudi 630 004, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-5916.200894

Rights and Permissions

Background & objectives: Epitope-based vaccines (EVs) are specific, safe and easy to produce. However, vaccine failure has been frequently reported due to variation within epitopic regions. Therefore, development of vaccines based on conserved epitopes may prevent such vaccine failure. This study was undertaken to identify highly conserved antigenic regions in the four dengue serotypes to produce an epitope-based dengue vaccine.
Methods: Polyprotein sequences of all four dengue serotypes were collected and aligned using MAFFT multiple sequence alignment plugin with Geneious Pro v6.1. Consensus sequences of the polyproteins for all four dengue serotypes were designed and screened against experimentally proven epitopes to predict potential antigenic regions that are conserved among all four dengue serotypes.
Results: The antigenic region VDRGWGNGCGLFGKG was 100 per cent conserved in the consensus polyprotein sequences of all four dengue serotypes. Fifteen experimentally proven epitopes were identical to the immunodominant antigenic region.
Interpretation & conclusions: Computationally predicted antigenic regions may be considered for use in the development of EVs for protection against dengue virus. Such vaccines would be expected to provide protection against dengue infections caused by all dengue serotypes because these would contain antigenic regions highly conserved across those serotypes. Therefore, the immunodominant antigenic region (VDRGWGNGCGLFGKG) and 15 potential epitopes may be considered for use in dengue vaccines.

Keywords: Antigenic region - dengue infection - epitope-based vaccine - sequence analysis

How to cite this article:
Muthusamy K, Gopinath K, Nandhini D. Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination. Indian J Med Res 2016;144:587-91

How to cite this URL:
Muthusamy K, Gopinath K, Nandhini D. Computational prediction of immunodominant antigenic regions & potential protective epitopes for dengue vaccination. Indian J Med Res [serial online] 2016 [cited 2021 Jul 28];144:587-91. Available from:

Dengue viruses (DENVs) are the aetiologic agent for dengue fever and can sometimes cause fatal haemorrhagic fever/shock syndrome. It is estimated that 50-100 million dengue infections occur annually in over 100 endemic countries [1]. In India, 201771 infected cases and 920 deaths were reported from 2007 to 2013 and in 2015 alone, 99913 infected cases were reported [2].

Vaccination may be the most viable option to prevent dengue infection, but unfortunately, it has been largely unsuccessful in preventing outbreaks. The ideal dengue vaccine must induce long-term immunity against all the four dengue serotypes. Even after more than 60 yr of research, a licensed vaccine against dengue is still elusive. At present, only 'candidate' dengue vaccines are available. Candidate dengue vaccine development has been based on a variety of technologies including live attenuated virus, recombinant proteins, chimeric vaccines, recombinant viral vectors and DNA vaccines [3]. Epitopes are the regions of an antigen that are bound by antigen-specific adaptive immune membrane receptors on lymphocytes or by secreted antibodies. Epitopes provide valuable information for disease prevention, diagnosis, treatment [4], and also represent a new strategy for prophylactic and therapeutic induction of pathogen-specific immunity [5]. Epitope-based vaccines (EVs) can induce both cellular (T-cell epitopes) and humoral (B-cell epitopes) immune responses. T-cell epitopes bind to major histocompatibility complex (MHC) and interact with the T-cell receptor, stimulating a T-cell response. B-cell epitopes interact with antibodies. Recognition of the appropriate peptide-MHC complexes by the antigen-specific receptor of T-lymphocytes leads to cell proliferation and a cascade of cellular immune responses [6]. MHC-II molecules bind longer peptides (15-20 amino acids), whereas MHC-I molecules bind shorter peptides (9 amino acids or less)[7]. Prediction of such epitope binding is critical. Hence, various computational algorithms and methods have been used for the prediction of epitopes [8] and mostly conserved epitopes should be considered for vaccine development [9].

The identification of immunodominant antigenic regions has significantly advanced the development of peptide-based vaccines. Potential advantages of the epitope-based approach include increased safety and the opportunity to rationally engineer epitopes for increased potency and breadth [10]. Antigenic regions induce a more specific immune response to a disease compared to other vaccination methods [11]. Computational approaches in predicting epitopes are an alternative to the expensive experimental discovery. However, computational methods may not predict functional protective epitopes due to variation among epitopic regions across strains or serotypes. Advantages of computational prediction of highly conserved epitopes for use in vaccines are the time saved and the safety of such vaccines [10].

This study was aimed to identify highly conserved antigenic regions in the four dengue serotypes (DENV1, DENV2, DENV3, DENV4) with the goal to develop an epitope-based dengue vaccine. Experimentally proven epitopes were used to identify potential immunodominant antigenic regions. These antigenic regions were identified by screening experimentally proven epitopes against consensus sequences from all four dengue polyproteins.

   Material & Methods Top

Computational methods were carried out in the Pharmacogenomics and Computer Aided Drug Design (CADD) Laboratory, Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India, during March-November 2013.

Sequence collection: To identify the conserved antigenic regions, all available DENV whole genomes for the four dengue serotypes were retrieved from the NCBI Nucleotide database [12]. Genomic regions, encoding for the polyproteins, were identified from GenBank ( The respective protein sequences were retrieved from the NCBI protein database ( and saved in FASTA format ( These four sets of protein sequences were used for the generation of consensus sequences from multiple sequences.

Multiple sequence alignment: Geneious Pro v6.1 (Biomatters Ltd, New Zealand)[13] was used for multiple sequence alignment (MSA) and consensus sequence generation from all four sets of polyprotein sequences. MSA was generated for polyproteins of all four serotypes using MAFFT Plugin [14]. FFT-NS1 algorithm [15], BLOSUM 62 was selected and Gap open penalty - 1.53 and Offset value 0.123 was set to generate MSA. MSA of four dengue serotype with 100 per cent identical sites (amino acid residue matching in all the sequences) was used for the generation of consensus sequence.

Collection of experimentally proved positive epitopes: The positive epitopes were collected from Immune Epitopes Database (IEDB)[16] which contains both positive and negative experimental results, to predict potential immunodominant antigenic regions in all serotypes. Experimentally proven positive epitope sequences were collected as these were previously shown to be recognized in the context of an immune response against the pathogen. The IEDB includes epitopes from all four serotypes (DENV1, DENV2, DENV3 and DENV4). The information associated with positive epitopes was exported as an excel file from the results page. This information included Epitope ID, peptide sequence, source antigen and source organism. Epitope sequences were collected from the exported excel file and saved in FASTA format. Dengue type, Epitope ID and position in polyprotein were added to the FASTA description line.

Identification of potential immunodominant antigenic region: The IEDB analysis resource was used to predict the antigenic region [17] conserved in all dengue serotypes. The epitope conservancy analysis tool was used to calculate the degree of conservancy of an epitope within a given protein sequence set at different degrees of sequence identity [18]. The positive epitopes of each serotype were screened against its respective consensus sequence. Epitopes having 100 per cent identity with its target consensus sequence were collected and saved in a single FASTA file. These collected sequences were again screened against all consensus sequences to predict antigenic regions conserved in all dengue serotypes. Epitopes having 100 per cent identity with four consensus sequences were considered highly conserved, and thus ideal candidates for EVs useful against all serotypes during dengue viral infection.

   Results Top

Sequence collection and generation of consensus sequence: All available whole genomes were retrieved from the NCBI nucleotide database. Whole genome information for the four types was collected in GenBank format. All four serotypes were differentiated, and protein sequences were collected from coding DNA sequences row with the sequences saved in FASTA format. Collected sequences were saved as separate files with FASTA extension. MSAs were generated for each serotype, and these MSAs were used to generate consensus sequences for further prediction of a conserved antigenic region among all serotypes.

Collection of experimentally proved positive epitopes: The IEDB includes both positive and negative epitopes; however; only positive epitopes (DENV1: 168, DENV2: 645, DENV3: 119 and DENV4: 79) were used to screen for potential antigenic regions.

Identification of immunodominant antigenic regions: To predict a conserved antigenic region among all four serotypes, epitopes from each dengue serotype (DENV1-289, DENV2-1290, DENV3-315 and DENV 4-95) were screened against their respective consensus sequence to find the degree of similarity between these sequences. Epitope sequences having 100 per cent identity with the target sequences were collected. A sum of 87 epitopes (DENV1-2, DENV2-55, DENV3-6 and DENV4-24) with 100 per cent identity to the target sequence were identified. These 87 sequences were combined together in a single FASTA file. These sequences were screened against all four serotypes to find the conserved immunodominant antigenic region. The antigenic region VDRGWGNGCGLFGKG was found to have no genetic variation and was conserved in all of the dengue polyproteins. This region was considered immunodominant as it was conserved in all four dengue serotypes. It is expected that this region will not allow antigenic resistance. Among these 87 sequences, only 15 epitopes had 100 per cent identity with this immunodominant antigenic region. These 15 epitopes were from the envelope glycoprotein and were experimentally tested against DENV with positive responses. Since this region was conserved among all four serotypes, it was expected to be potentially protective against all four dengue types. The [Table 1] provides information about predicted 15 potential immunodominant antigenic regions along with the experimental details obtained from the IEDB for the predicted epitopes [19],[20],[21],[22].
Table 1: Details concerning predicted 15 potential immunodominant antigenic regions that have 100 per cent identity with all four serotypes

Click here to view

   Discussion Top

Traditional vaccines are based on the intact pathogen, either inactivated or live attenuated, or proteins [23]. EVs are able to immunize using the minimal structure, consisting of a well-defined antigen, with respect to its antigenicity and immunogenicity. However, in clinical usage, some EVs have failed to protect against pathogens. Therefore, development of a vaccine based on conserved epitopes may avoid such antigenic resistance [24].

Computational approaches in predicting T-cell epitopes and analysis of sequence conservation have been widely used for the epitope-based vaccination against various pathogens such as HIV-1, Vaccinia virus, DENV, West Nile virus, bacteria and protozoan parasites [25]. It is a powerful alternative strategy for the experimental discovery of candidate epitopes which is less expensive [26]. The major concern with the experimental approach for screening of positive epitopes is that these may be too narrow in scope and may not be effective against other pathogens or in different hosts. This challenge for EVs may be overcome by identifying epitopes conserved across multiple strains/serotype of an organism to protect against a genetically diverse community [27]. The in silico prediction of potential immunodominant antigenic regions is another approach that can greatly reduce the time and effort involved in screening potential epitopes [28]. Thus, this approach can be used as a template for the analysis of other pathogens, providing a novel and generalized approach to the formulation of EVs that are effective against a broad diversity of pathogens [27].

In this study, an immunodominant antigenic region VDRGWGNGCGLFGKG was found to be conserved (100%) in all dengue polyprotein sequences. Conserved regions in the viral protein sequences are the prime target for EV formulation [29]. The use of this antigenic region in EVs would confer broader protection across multiple strains [30] because these antigenic regions are conserved throughout the evolution. In this study 15 experimentally proven epitopes with 100 per cent identity to this immunodominant antigenic region were identified. Since the immunodominant antigenic region is conserved in all dengue serotypes, it is anticipated that identified peptides from DENV1 and DENV2 would also elicit immune responses against all other serotypes. The antigenicity of the identified polypeptide was previously verified using the ELISA method [19],[20],[21],[22]. Hence, these 15 polypeptides may be considered as potentially protective epitopes for use in dengue vaccination and are expected to overcome the problem of the shift of antigenic sites due to drug resistance and may also have the potential to trigger an immune response against all four dengue serotypes.

   Acknowledgment Top

Authors acknowledge the infrastructure facilities provided by the Department of Bioinformatics, Alagappa University, Postgraduate Diploma in Structural Pharmacogenomics (funded by UGC, Government of India).

Conflicts of Interest: None.

   References Top

Dengue and severe dengue. Geneva: World Health Organization; 2014. Available from:, accessed on January 8, 2014.  Back to cited text no. 1
Dengue. Delhi: Directorate of National Vector Borne Disease Control Programme (NVBDCP); Available from:, accessed on January 13, 2016.  Back to cited text no. 2
Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5 : 518-28.  Back to cited text no. 3
Goldsby RA, Kindt TJ, Kuby J, Osborne BA. Immunology. 5th ed. New York: W. H. Freeman; 2002.  Back to cited text no. 4
Khan AM, Miotto O, Heiny AT, Salmon J, Srinivasan KN, Nascimento EJ, et al. A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cell Immunol 2006; 244 : 141-7.  Back to cited text no. 5
Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991; 9 : 527-65.  Back to cited text no. 6
McFarland BJ, Beeson C. Binding interactions between peptides and proteins of the class II major histocompatibility complex. Med Res Rev 2002; 22 : 168-203.  Back to cited text no. 7
Bremel RD, Homan EJ. An integrated approach to epitope analysis I: dimensional reduction, visualization and prediction of MHC binding using amino acid principal components and regression approaches. Immunome Res 2010; 6 : 7.  Back to cited text no. 8
Good MF, Berzofsky JA, Miller LH. The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. Annu Rev Immunol 1988; 6 : 663-88.  Back to cited text no. 9
Sette A, Keogh E, Ishioka G, Sidney J, Tangri S, Livingston B, et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Investig Drugs 2002; 3 : 132-9.  Back to cited text no. 10
Toussaint NC, Kohlbacher O. Towards in silico design of epitope-based vaccines. Expert Opin Drug Discov 2009; 4 : 1047-60.  Back to cited text no. 11
Nucleotide. Bethesda, MD: National Library of Medicine (US); 1999. Available from:, accessed on July 15, 2013.  Back to cited text no. 12
Drummond AJ, Ashton B, Buxton S, Cheung M, Cooper A, Duran C, et al. Geneious 5.4 [Software Created by Biomatters Ltd., Auckland, New Zealand], 2011. Available from:, accessed on October 9, 2014.  Back to cited text no. 13
Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 2013; 30 : 772-80.  Back to cited text no. 14
Feng DF, Doolittle RF. Progressive sequence alignment as a prerequisite to correct phylogenetic trees. J Mol Evol 1987; 25 : 351-60.  Back to cited text no. 15
Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38 : D854-62.  Back to cited text no. 16
Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, et al. Immune epitope database analysis resource. Nucleic Acids Res 2012; 40 : W525-30.  Back to cited text no. 17
Bui HH, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinformatics 2007; 8 : 361.  Back to cited text no. 18
Lund O, Nascimento EJ, Maciel M Jr., Nielsen M, Larsen MV, Lundegaard C, et al. Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One 2011; 6 : e26494.  Back to cited text no. 19
Innis BL, Thirawuth V, Hemachudha C. Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus. Am J Trop Med Hyg 1989; 40 : 676-87.  Back to cited text no. 20
Falconar AK. Monoclonal antibodies that bind to common epitopes on the dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak neutralizing activity and differentiated responses to virulent strai ns: implications for pathogenesis and vaccines. Clin Vaccine Immunol 2008; 15 : 549-61.  Back to cited text no. 21
Aaskov JG, Geysen HM, Mason TJ. Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). Arch Virol 1989; 105 : 209-21  Back to cited text no. 22
Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open Biol 2013; 3 : 120139.  Back to cited text no. 23
Claesson MH. Why current peptide-based cancer vaccines fail: lessons from the three Es. Immunotherapy 2009; 1 : 513-6.  Back to cited text no. 24
Desai DV, Kulkarni-Kale U. T-cell epitope prediction methods: an overview. Methods Mol Biol 2014; 1184 : 333-64.  Back to cited text no. 25
Sánchez-Burgos G, Ramos-Castañeda J, Cedillo-Rivera R, Dumonteil E. Immunogenicity of novel dengue virus epitopes identified by bioinformatic analysis. Virus Res 2010; 153 : 113-20.  Back to cited text no. 26
Bremel RD, Homan EJ. An integrated approach to epitope analysis II: a system for proteomic-scale prediction of immunological characteristics. Immunome Res 2010; 6 : 8.  Back to cited text no. 27
De Groot AS, Berzofsky JA. From genome to vaccine – New immunoinformatics tools for vaccine design. Methods 2004; 34 : 425-8.  Back to cited text no. 28
Tong JC, Ren EC. Immunoinformatics: current trends and future directions. Drug Discov Today 2009; 14 : 684-9.  Back to cited text no. 29
Staneková Z, Varecková E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010; 7 : 351.  Back to cited text no. 30


  [Table 1]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Material & M...
    Article Tables

 Article Access Statistics
    PDF Downloaded256    
    Comments [Add]    

Recommend this journal